- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02223754
Evaluation of an Investigational Multifocal Lens
18 giugno 2018 aggiornato da: Johnson & Johnson Vision Care, Inc.
The purpose of this study is to test the performance of an investigational multifocal test soft contact lens.
Panoramica dello studio
Stato
Completato
Condizioni
Intervento / Trattamento
Tipo di studio
Interventistico
Iscrizione (Effettivo)
371
Fase
- Non applicabile
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
Alabama
-
Montgomery, Alabama, Stati Uniti, 36109
-
-
California
-
Mission Viejo, California, Stati Uniti, 92691
-
-
Florida
-
Jacksonville, Florida, Stati Uniti, 32205
-
Jacksonville, Florida, Stati Uniti, 32250
-
Orange Park, Florida, Stati Uniti, 32065
-
Saint Augustine, Florida, Stati Uniti, 32092
-
Tallahassee, Florida, Stati Uniti, 32308
-
Tampa, Florida, Stati Uniti, 33625
-
Winter Park, Florida, Stati Uniti, 32792
-
-
Georgia
-
Roswell, Georgia, Stati Uniti, 30076
-
-
Kansas
-
Pittsburg, Kansas, Stati Uniti, 66762
-
-
Michigan
-
East Lansing, Michigan, Stati Uniti, 48823
-
-
New York
-
Vestal, New York, Stati Uniti, 13850
-
-
North Carolina
-
Denver, North Carolina, Stati Uniti, 28037
-
-
Ohio
-
Powell, Ohio, Stati Uniti, 43065
-
Springfield, Ohio, Stati Uniti, 45503
-
-
Rhode Island
-
Warwick, Rhode Island, Stati Uniti, 02888
-
-
Tennessee
-
Memphis, Tennessee, Stati Uniti, 38119
-
-
Texas
-
Tyler, Texas, Stati Uniti, 75701
-
-
Virginia
-
Salem, Virginia, Stati Uniti, 24153
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
Da 40 anni a 70 anni (Adulto, Adulto più anziano)
Accetta volontari sani
Sì
Sessi ammissibili allo studio
Tutto
Descrizione
Inclusion Criteria:
- The subjects were required to have read, understand, and signed the Statement of Informed Consent and receive a fully executed copy of the form.
- The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.
- Between 40 and 70 years of age.
- Subjects must own a wearable pair of spectacles, if required for their distance vision.
- Be an adapted soft contact lens wearer in both eyes (i.e. worn lenses a minimum of 2 days per week for at least 8 hours per wear day, for 1 month of more duration)
- Already be wearing a presbyopic contact lens correction (e.g., reading spectacles over contact lenses, multifocal or monovision contact lenses, etc.) or if not respond positively to at least one symptom on the "Presbyopic Symptoms Questionnaire"*
- The subject's vertex corrected spherical equivalent distance refraction was required to be in the range +3.50 to -5.75 in each eye.
- Refractive cylinder ≤ -0.75 D in each eye.
- ADD power in the range +0.75 D to +2.50 D in each eye.
- Best corrected visual acuity of 20/20-3 or better in each eye.
Exclusion Criteria:
- Currently pregnant or lactating (subjects who became pregnant during the study were discontinued).
- Any ocular or systemic allergies that may have contraindicated contact lens wear.
- Any ocular or systemic disease, autoimmune disease, or use of medication, that may have contraindicated contact lens wear.
- Any ocular abnormality that may have interfered with contact lens wear.
- Use of any ocular medication, with the exception of rewetting drops.
- Any previous intraocular surgery (e.g., radial keratotomy, PRK, LASIK, etc.).
- History of herpetic keratitis.
- History of binocular vision abnormality or strabismus.
- Any infectious disease (e.g., hepatitis, tuberculosis) or a contagious immunosuppressive disease (e.g., HIV).
- History of diabetes.
- Participation in any contact lens or lens care product clinical trial within 30 days prior to study enrollment.
- Any Grade 3 or greater slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) which may contraindicate contact lens wear.
- Any ocular infection or inflammation.
- Any corneal distortion or irregular cornea.
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: lotrafilcon B / etafilcon A
Subject randomized to this sequence will first be dispensed the lotrafilcon B contact lens and then the etafilcon A contact lens.
|
Soft contact lens to be worn as daily wear, monthly replacement modality.
Altri nomi:
Soft contact lens to be worn as daily wear, daily disposable modality.
|
|
Sperimentale: etafilcon A / lotrafilcon B
Subject randomized to this sequence will first be dispensed the etafilcon A contact lens and then the lotrafilcon B contact lens.
|
Soft contact lens to be worn as daily wear, monthly replacement modality.
Altri nomi:
Soft contact lens to be worn as daily wear, daily disposable modality.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Overall Quality of Vision Using the Contact Lens User Experience (CLUE) TM Questionnaire
Lasso di tempo: 8 -12 days post wear
|
CLUE Overall Quality of Vision is assessed using the Contact Lens User Experience (CLUE)TM questionnaire.
CLUE is a validated patient-reported outcomes questionnaire to assess patient experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65.
Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response.
97% of the scores fall within 0 and 120 (mean +/-3XSD).
|
8 -12 days post wear
|
|
Distance Binocular Visual Acuity (LogMAR)
Lasso di tempo: 8- 12 Days post wear
|
Distance time controlled LogMAR Visual Acuity was carried out binocularly with high luminance and high contrast.
|
8- 12 Days post wear
|
|
Intermediate Binocular Visual Acuity (LogMAR)
Lasso di tempo: 8-12 days post wear
|
Intermediate time controlled LogMAR Visual Acuity was carried out binocularly using High lumiance and High Contrast.
|
8-12 days post wear
|
|
Near Binocular Visual Acuity (LogMAR)
Lasso di tempo: 8-12 days post wear
|
Near time controlled LogMAR Visual Acuity was carried out binocularly using High lumiance and High Contrast.
|
8-12 days post wear
|
|
Corneal Staining
Lasso di tempo: 8 - 12 Days post wear
|
Corneal staining is evaluated using Sodium Fluorescein strips.
The Fluorescien strip was lightly placed on the subject's inferior palpebral conjunctiva.
The corneal Staining was graded using the scale Grade 0: No Staining, Grade 1: Trace(Minimal superficial staining or stippling), Grade 2: Mild (Regional or diffuse punctate staining), Grade 3:Moderate(Significant dense coalesced staining, corneal abrasion or foreign body tracks.),
Grade 4 Severe(Severe abrasions greater than 2 mm in diameter, ulcerations, epithelial loss, or full thickness abrasion.).
The data was dichotomized into two group subjects with grade 3 or higher staining, and those subjects with less than Grade 3. Below the percentage of subject eyes with grade 3 or higher is reported for each lens.
|
8 - 12 Days post wear
|
|
Bulbar Conjunctival Injection
Lasso di tempo: 8- 12 Days post wear
|
The bulbar is the scelra.
Bulbar Conjunctival Injection was assessed using an Efron Grading scale by 1 unit increments.
Grade 0: Normal, Grade 1: Trace, Grade 2: Mild, Grade 3: Moderate, Grade 4:Severe.
The data was dichotomized into two group subjects with grade 3 or higher Conjunctival injection, and those subjects with less than Grade 3. Below the percentage of subject eyes with grade 3 or higher is reported for each lens.
|
8- 12 Days post wear
|
|
Limbal Conjunctival Injection
Lasso di tempo: 8- 12 Days post wear
|
The Limbus is the 1 to 2mm wide zone of conjunctiva and underlying tissue adjacent to where the cornea joins the sclera.
Limbal Conjunctival Injection was assesed using the Efron grading scale in 1 unit increments.
Grade 0: Normal, Grade 1: Trace, Grade 2: Mild, Grade 3: Moderate, Grade 4:Severe.
The data was dichotomized into two group subjects with grade 3 or higher Conjunctival injection, and those subjects with less than Grade 3. Below the percentage of subject eyes with grade 3 or higher is reported for each lens.
|
8- 12 Days post wear
|
|
Contact Lens Fitting
Lasso di tempo: 8- 12 Days post wear
|
Contact Lens fitting is reported as a binary response.
Yes- acceptable lens fit, No- unacceptable lens fit.
The percentage of subject eyes with acceptable fit is reported.
|
8- 12 Days post wear
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio
1 agosto 2014
Completamento primario (Effettivo)
1 novembre 2014
Completamento dello studio (Effettivo)
1 novembre 2014
Date di iscrizione allo studio
Primo inviato
20 agosto 2014
Primo inviato che soddisfa i criteri di controllo qualità
20 agosto 2014
Primo Inserito (Stima)
22 agosto 2014
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
19 giugno 2018
Ultimo aggiornamento inviato che soddisfa i criteri QC
18 giugno 2018
Ultimo verificato
1 luglio 2016
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- CR-5593
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su lotrafilcon B
-
Indiana UniversityAlcon ResearchCompletato
-
CIBA VISIONUniversity of WaterlooCompletato
-
Johnson & Johnson Vision Care, Inc.CompletatoAcuità visivaAustralia
-
Johnson & Johnson Vision Care, Inc.Visioncare Research Ltd.Completato
-
CooperVision, Inc.Completato
-
Johnson & Johnson Vision Care, Inc.CompletatoSecchezza oculareRegno Unito
-
Alcon ResearchCompletato
-
Johnson & Johnson Vision Care, Inc.Completato
-
CooperVision, Inc.Completato
-
CooperVision, Inc.Completato